Abbott Laboratories Balance Sheet Health
Financial Health criteria checks 6/6
Abbott Laboratories has a total shareholder equity of $40.0B and total debt of $15.0B, which brings its debt-to-equity ratio to 37.6%. Its total assets and total liabilities are $74.4B and $34.3B respectively. Abbott Laboratories's EBIT is $7.6B making its interest coverage ratio 31.7. It has cash and short-term investments of $7.8B.
Key information
37.6%
Debt to equity ratio
US$15.05b
Debt
| Interest coverage ratio | 31.7x |
| Cash | US$7.79b |
| Equity | US$40.03b |
| Total liabilities | US$34.33b |
| Total assets | US$74.36b |
Recent financial health updates
Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?
Oct 11
These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well
Jul 01Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly
Mar 06Recent updates
Investors Will Want Abbott Laboratories' (NYSE:ABT) Growth In ROCE To Persist
Oct 31Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation
Oct 21Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event
Oct 14Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?
Oct 11Why We're Not Concerned About Abbott Laboratories' (NYSE:ABT) Share Price
Sep 27Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change
Sep 11A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Aug 16Abbott Laboratories: Driving Value By Scaling Innovations
Aug 13Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors
Aug 05Abbott Laboratories: When Double-Digit Device Growth Apparently Isn't Enough
Jul 13These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well
Jul 01Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price
Jun 18Investors Still Waiting For A Pull Back In Abbott Laboratories (NYSE:ABT)
Jun 04Abbott Laboratories: Why I Agree With Wall Street On This One
Jun 04Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock
May 18Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings
Apr 17Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Apr 15Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now
Mar 21Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger
Mar 19Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly
Mar 06Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024
Feb 27Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon
Feb 08The King Is Back: Abbott Laboratories' Path To >11% Annual Returns
Jan 29The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts
Jan 26Financial Position Analysis
Short Term Liabilities: ABT's short term assets ($23.8B) exceed its short term liabilities ($14.9B).
Long Term Liabilities: ABT's short term assets ($23.8B) exceed its long term liabilities ($19.4B).
Debt to Equity History and Analysis
Debt Level: ABT's net debt to equity ratio (18.1%) is considered satisfactory.
Reducing Debt: ABT's debt to equity ratio has reduced from 59.6% to 37.6% over the past 5 years.
Debt Coverage: ABT's debt is well covered by operating cash flow (58%).
Interest Coverage: ABT's interest payments on its debt are well covered by EBIT (31.7x coverage).